Clinical Challenges of Pediatric MS

Volume 3, Issue 8

Clinical Challenges of Pediatric MS

In this issue:

Pediatric multiple sclerosis. How different is the disease from adult MS? Which disease-modifying therapies have been trialed and approved for use in children? How common is cognitive impairment in children with MS? How can it be successfully addressed?

These are some of the important questions Drs. Zongqi Xia and Kavita Thakkar from the University of Pittsburgh Medical Center discuss in this clinically focused eMultipleSclerosis Review podcast.

Learning objectives:

Describe the disease modifying therapies appropriate for treatment of children with MS.
Explain the differences in MS disease activity between children and adults.

Authors:

Zongqi Xia, MD, PhD

Assistant Professor of Neurology, Biomedical Informatics and Bioengineering
University of Pittsburgh School of Medicine
Pittsburg, PA

Kavita Thakkar, MD

Assistant Professor of Pediatrics and Neurology
Department of Pediatrics and Neurology
University of Pittsburgh School of Medicine
Pittsburgh, PA

Guest Faculty Disclosures

Dr. Thakkar has indicated that she has no financial interests or relationships with a commercial entity.  

Dr. Xia has disclosed that he has received consulting fees (scientific advisory board) from Genentech, Inc. and consulting fees (contracted research) from Octave Bioscience. 

Unlabeled/Unapproved Uses

The authors will discuss the practical uses of non-approved medications in pediatric multiple sclerosis. Except for fingolimod, no other MS drugs are FDA approved for use in children with MS. 

Program Directors:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Guest Faculty Disclosures:

Dr. Thakkar has indicated that she has no financial interests or relationships with a commercial entity.  

Dr. Xia has disclosed that he has received consulting fees (scientific advisory board) from Genentech, Inc. and consulting fees (contracted research) from Octave Bioscience. 

Unlabeled/Unapproved Uses:

The authors will discuss the practical uses of non-approved medications in pediatric multiple sclerosis. Except for fingolimod, no other MS drugs are FDA approved for use in children with MS. 

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: December 27, 2020
Expiration date: December 26, 2022

Start Issue